

Sylvain Goutelle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3282908/publications.pdf>

Version: 2024-02-01

65
papers

1,925
citations

471061

17
h-index

276539

41
g-index

66
all docs

66
docs citations

66
times ranked

2935
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonparametric Methods in Population Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 142-157.	1.0	28
2	Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 158-170.	1.0	9
3	Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 86-102.	1.0	10
4	Pharmacokinetic/Pharmacodynamic Simulations of Cost-Effective Dosage Regimens of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Patients with Renal Impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0210421.	1.4	2
5	Implementation and Comparison of Two Pharmacometric Tools for Model-Based Therapeutic Drug Monitoring and Precision Dosing of Daptomycin. <i>Pharmaceutics</i> , 2022, 14, 114.	2.0	8
6	Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0204621.	1.4	9
7	Subcutaneous Antibiotic Therapy: The Why, How, Which Drugs and When. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 50-55.e6.	1.2	20
8	Drug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 208-216.	1.0	2
9	Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1250-1257.	1.3	9
10	Pharmacokinetic/Pharmacodynamic Dosage Individualization of Suppressive Beta-Lactam Therapy Administered by Subcutaneous Route in Patients With Prosthetic Joint Infection. <i>Frontiers in Medicine</i> , 2021, 8, 583086.	1.2	7
11	Rifampicin exposure reveals within-host <i>Mycobacterium tuberculosis</i> diversity in patients with delayed culture conversion. <i>PLoS Pathogens</i> , 2021, 17, e1009643.	2.1	10
12	Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab351.	0.4	4
13	To Estimate or to Forecast? Lessons From a Comparative Analysis of Four Bayesian Fitting Methods Based on Nonparametric Models. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 461-471.	1.0	4
14	Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0104321.	1.4	13
15	Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0073721.	1.4	5
16	Amikacin in emergency surgery: how to dose it optimally?. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 41, 100990.	0.6	1
17	Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8. <i>Clinical Pharmacokinetics</i> , 2020, 59, 757-770.	1.6	5
18	A Population Pharmacokinetic Analysis of Continuous Infusion of Cloxacillin during <i>Staphylococcus aureus</i> Bone and Joint Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	8

#	ARTICLE	IF	CITATIONS
19	Outpatient Subcutaneous Antimicrobial Therapy (OSCAT) as a Measure to Improve the Quality and Efficiency of Healthcare Delivery for Patients With Serious Bacterial Infections. <i>Frontiers in Medicine</i> , 2020, 7, 585658.	1.2	7
20	Tolerance and microbiological efficacy of cefepime or piperacillin/tazobactam in combination with vancomycin as empirical antimicrobial therapy of prosthetic joint infection: a propensity-matched cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2299-2306.	1.3	5
21	Azithromycin for COVID-19: More Than Just an Antimicrobial?. <i>Clinical Drug Investigation</i> , 2020, 40, 683-686.	1.1	83
22	Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1049-1061.	1.6	18
23	Medical innovations to maintain the function in patients with chronic PJI for whom explantation is not desirable: a pathophysiology-, multidisciplinary-, and experience-based approach. <i>Sicot-j</i> , 2020, 6, 26.	0.8	9
24	Goal-Oriented Monitoring of Cyclosporine Is Effective for Graft-versus-Host Disease Prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia Major. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2285-2291.	2.0	3
25	Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children. <i>Bone Marrow Transplantation</i> , 2019, 54, 448-457.	1.3	31
26	Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1012-1020.	1.3	12
27	Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize <i>A Priori</i> Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16
28	Subcutaneous suppressive antibiotic therapy for bone and joint infections: safety and outcome in a cohort of 10 patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2060-2064.	1.3	15
29	Optimization of the treatment with beta-lactam antibiotics in critically ill patientsâ€”guidelines from the French Society of Pharmacology and Therapeutics (Soci�t� Fran�saise de Pharmacologie et) <i>Tj ETQq1 1 0.784314 rgBT /Overlo</i>	2.5	299
30	Determinants of amikacin first peak concentration in critically ill patients. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 669-677.	1.0	5
31	Comment on: MIC-based dose adjustment: facts and fables. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2584-2585.	1.3	7
32	Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 987-994.	1.3	19
33	Identification of Cytochrome P450-Mediated Drug�Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1581-1591.	1.6	8
34	Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using <i>In Vitro</i> Experiments and Response-Surface Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	9
35	Correction of Linezolid-Induced Myelotoxicity After Switch to Tedizolid in a Patient Requiring Suppressive Antimicrobial Therapy for Multidrug-Resistant Staphylococcus epidermidis Prosthetic-Joint Infection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy246.	0.4	16
36	Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages. <i>Tuberculosis</i> , 2018, 111, 67-70.	0.8	24

#	ARTICLE	IF	CITATIONS
37	Prospective Cohort Study of the Tolerability of Prosthetic Joint Infection Empirical Antimicrobial Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	13
38	Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	9
39	Mechanisms of drug-drug interaction between rifampicin and fusidic acid. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1862-1864.	1.1	4
40	Prevalence and Risk Factors of Drug-Associated Corrected QT Prolongation in Elderly Hospitalized Patients: Results of a Retrospective Analysis of Data Obtained Over 6 Months. <i>Drugs and Aging</i> , 2017, 34, 545-553.	1.3	5
41	A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics. <i>Clinical Pharmacokinetics</i> , 2017, 56, 435-447.	1.6	11
42	Implications of using the MDRD or CKD-EPI equation instead of the Cockcroft-Gault equation for estimating renal function and drug dosage adjustment in elderly patients. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 110-119.	1.0	24
43	Comparison of the static <i>in vivo</i> approach to a physiologically based pharmacokinetic approach for metabolic drug-drug interactions prediction. <i>International Journal of Pharmacokinetics</i> , 2016, 1, 25-34.	0.5	10
44	Bayesian network to optimize the first dose of antibiotics: application to amikacin. <i>International Journal of Pharmacokinetics</i> , 2016, 1, 35-42.	0.5	4
45	Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 332-342.	1.0	53
46	Mathematical modeling and systems pharmacology of tuberculosis: Isoniazid as a case study. <i>Journal of Theoretical Biology</i> , 2016, 399, 43-52.	0.8	9
47	Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3148-3151.	1.4	19
48	Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers. <i>Clinical Pharmacokinetics</i> , 2016, 55, 977-990.	1.6	23
49	Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure. <i>Clinical Pharmacokinetics</i> , 2015, 54, 319-320.	1.6	0
50	A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells using rifampicin as an example. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 313-319.	0.8	14
51	A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1245-1258.	1.6	14
52	Influence of Renal Function Estimation on Pharmacokinetic Modeling of Vancomycin in Elderly Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2986-2994.	1.4	20
53	Pharmacokinetic Drug Interaction Between Cyclosporine and Imatinib in Bone Marrow Transplant Children and Model-Based Reappraisal of Imatinib Drug Interaction Profile. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 724-729.	1.0	10
54	Determinants of Torsades de Pointes in Older Patients with Drug-Associated Long QT Syndrome: A Case-Control Study. <i>Drugs and Aging</i> , 2014, 31, 601-609.	1.3	11

#	ARTICLE	IF	CITATIONS
55	The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy. <i>Current Pharmaceutical Design</i> , 2014, 20, 6191-6206.	0.9	11
56	In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates. <i>AAPS Journal</i> , 2013, 15, 415-426.	2.2	39
57	Pharmacokinetic-Pharmacodynamic Modeling of Unboosted Atazanavir in a Cohort of Stable HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 517-523.	1.4	14
58	Comparison of Four Renal Function Estimation Equations for Pharmacokinetic Modeling of Gentamicin in Geriatric Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1862-1869.	1.4	28
59	The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 279-285.	1.0	10
60	Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2011, 50, 519-530.	1.6	43
61	Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin. <i>Journal of Theoretical Biology</i> , 2011, 282, 80-92.	0.8	24
62	Oral Voriconazole Dose in Children: One Size Does Not Fit All. <i>Clinical Infectious Diseases</i> , 2010, 51, 870-870.	2.9	10
63	Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2974-2981.	1.4	96
64	Visual estimation of patients' body weight in hospital: the more observers, the better?. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 422-425.	1.4	11
65	The Hill equation: a review of its capabilities in pharmacological modelling. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 633-648.	1.0	645